Valeant Pharmaceuticals International Company Profile (NYSE:VRX)

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals International (NYSE:VRX) (?)
Ratings Breakdown: 4 Sell Rating(s), 16 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: $60.69 (158.35% upside)

Analysts' Ratings History for Valeant Pharmaceuticals International (NYSE:VRX)
Show:
DateFirmActionRatingPrice TargetActions
7/26/2016ScotiabankReiterated RatingSector Perform$35.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016MizuhoReiterated RatingUnderperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/25/2016JPMorgan Chase & Co.Set Price TargetHold$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016BMO Capital MarketsReiterated RatingMarket Perform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016RBC Capital MarketsReiterated RatingSector Perform$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Canaccord GenuityReiterated RatingHold$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016TD SecuritiesReiterated RatingHold$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Wells Fargo & Co.Reiterated RatingSell$19.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Rodman & RenshawReiterated RatingBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016Stifel NicolausReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2016Royal Bank Of CanadaReiterated RatingSector PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016BTIG ResearchReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016GuggenheimReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Jefferies GroupReiterated RatingBuy$53.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Barclays PLCReiterated RatingHold$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Piper Jaffray Cos.Reiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Morgan StanleyReiterated RatingHold$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016SusquehannaReiterated RatingHold$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016NomuraReiterated RatingNeutral$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016Deutsche Bank AGReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015Bank of America Corp.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/23/2015Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Goldman Sachs Group Inc.DowngradeBuy -> Neutral$180.00 -> $122.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/19/2015Evercore ISIReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2015Howard WeilInitiated CoverageOutperform$290.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2015Cantor FitzgeraldBoost Price TargetBuy$222.00 -> $271.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015CRT CapitalBoost Price TargetBuy$180.00 -> $220.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/20/2014AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012$0.99$1.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012$0.96$0.99ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011$0.57$0.66ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011$0.65$0.73ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2011$0.51$0.56ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011$0.45$0.51ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Valeant Pharmaceuticals International (NYSE:VRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$1.60$1.60$1.60
Q3 20161$1.83$1.83$1.83
Q4 20161$2.10$2.10$2.10
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Valeant Pharmaceuticals International (NYSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Valeant Pharmaceuticals International (NYSE:VRX)
DateHeadline
07/27/16 07:39 PMInvestors Trading Alert: Valeant Pharmaceuticals International, Inc ... - Street Updates
07/27/16 10:08 AMFactors That Could Lead to More Growth for Acthar -
07/26/16 07:44 PMAnalysts watching two Stocks: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Ionis Pharmaceuticals Inc ... - Street Updates
07/25/16 06:25 AMValeant Pharmaceuticals: That Was Not Bad News, Was It? - Seeking Alpha
07/24/16 05:41 PMAckman's Bad Bets Costs $600 Million in Redemptions -
07/24/16 05:40 AMValeant Pharmaceuticals International, Inc (VRX): FDA Letter Outlines Concerns, Shares Slip - TCC
07/22/16 10:05 AMValeant Pharma (VRX) Receives FDA CRL on Eye Drops Related to Manufacturing Deficiencies; No NDA Efficacy, Safety Concerns Noted
07/22/16 10:05 AMValeant Pharmaceuticals Intl Inc (VRX): FDA Letter Outlines Concerns, Shares Slip
07/22/16 10:05 AMFDA Dents Bullish Options Hopes on Valeant Pharmaceuticals Intl Inc (VRX)
07/22/16 09:34 AMValeant: Not All Delays Are Created Equal -
07/22/16 09:02 AMValeant (VRX) Stock Down on Concerns About Glaucoma Treatment -
07/22/16 07:44 AMMorning Movers: General Electric Falls on Earnings; Valeant Drops -
07/22/16 06:58 AMValeant Drug Approval Hampered by FDA Facility Inspection -
07/22/16 02:36 AMU.S. FDA raises concerns over Valeant's eye drop - [Reuters] - Valeant Pharmaceuticals International said on Friday U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida. The U.S. Food and Drug Administration, in a complete response letter (CRL) regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit. The letter did not identify any efficacy or safety issues with the eye drop, a latanoprostene bunod ophthalmic solution.
07/22/16 01:32 AM2:32 am Valeant Pharma receives Complete Response Letter from the FDA regarding the New Drug Application for latanoprostene bunod ophthalmic solution -
07/22/16 01:00 AMValeant Pharmaceuticals Receives Complete Response Letter From The FDA - [CNW Group] - Valeant Pharmaceuticals Receives Complete Response Letter From The FDA
07/21/16 07:32 PMFDA Experts Back Brodalumab, With Warnings - Seeking Alpha
07/21/16 07:32 PMEquity Roundup: Stock Performance Focus on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Press Telegraph
07/21/16 07:32 PMBiotechnology Stocks in the Spotlight: Galena Biopharma Inc (NASDAQ:GALE), Valeant Pharmaceuticals Intl Inc ... - Post Registrar
07/21/16 07:32 PMProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Spike on FDA ... - Journal Transcript
07/21/16 07:32 PMValeant Pharmaceuticals International Inc (NYSE:VRX) Realized Volatility Hits A Notable High - CML News
07/21/16 07:32 PMValeant Pharmaceuticals Intl Inc (VRX): A Bull And Bear Duke It Out - ValueWalk
07/21/16 07:32 PMRodman & Renshaw Shines Light on Valeant Pharmaceuticals Intl Inc (VRX) as Brodalumab and Oral Relistor Pass ... - Smarter Analyst
07/21/16 10:01 AMValeant Pharmaceuticals Intl Inc: This Could Send Valeant Stock Soaring
07/21/16 09:39 AMValeant & Endo: Imagining a World With No Drug Pricing Controversies -
07/20/16 08:16 PMValeant: FDA News Coming Fast And Furious
07/20/16 10:02 AMValeant Pharmaceuticals International (NYSE:VRX) Under Major Concerns- Manhattan Associates (NASDAQ:MANH ... - Seneca Globe
07/20/16 10:02 AMNoteworthy Analyst's Rating to Observe: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , GlaxoSmithKline ... - Street Updates
07/20/16 10:01 AMPershing Square Second Quarter Results--Live! -
07/20/16 09:41 AMStocks Move Higher as Crude Oil Pares Losses -
07/20/16 09:22 AMValeant Pharmaceuticals: Two for Two -
07/20/16 09:19 AMJim Cramer -- Valeant Needs These New Drug Approvals -
07/20/16 09:07 AMValeant (VRX) Stock Gains as FDA Approves Anticonstipation Drug -
07/20/16 09:05 AMCould This Be the Turning Point for Progenics and Valeant? -
07/19/16 07:21 PMHealthcare Stocks Grab Market Attentions- CytRx (NASDAQ:CYTR), Valeant Pharmaceuticals International (NYSE:VRX) - Seneca Globe
07/19/16 07:21 PMNotable Hot Runners: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Mondelez International Inc (NASDAQ:MDLZ) - NYSE Journal (press release)
07/19/16 05:50 PMInvestors Pull $600M After Ackman’s Bad Bets -
07/18/16 05:49 PMValeant's (VRX) Brodalumab BLA Up for Review in the U.S. -
07/18/16 03:53 PMValeant Stock Surges Ahead of Anticipated Drug Approval -
07/18/16 03:30 PMValeant Partnership With Walgreens in Trouble: Andrew Left -
07/18/16 01:30 PMValeant-Walgreens Partnership Destined to Flop, Andrew Left Says -
07/18/16 06:10 AMShares of Valeant Pharmaceuticals International (VRX) Drops by -1.68% - TheFounders Daily
07/18/16 06:10 AMNext Weeks Broker Price Targets For Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Fiscal Standard
07/18/16 12:00 AMPharming Announces Positive Results from Randomized Controlled Trial with RUCONEST® for HAE Prophylaxis - [PR Newswire] - Pharming Group N.V. ("Pharming" or "the Company") (PHARM.AS) today announced positive results from a Phase 2 clinical study of RUCONEST® (recombinant C1 esterase inhibitor, 50 IU/kg) for prophylaxis in patients with hereditary angioedema (HAE). In the study, RUCONEST® showed a clinically relevant and statistically significant reduction in attack frequency for both the twice-weekly and once-weekly treatment regimens as compared with placebo. Thirty-two HAE patients deficient in C1 esterase inhibitor and with a history of at least four attacks per month were enrolled in the randomized, double-blind, placebo-controlled study. The patients received RUCONEST® once and twice weekly and placebo in each of three four-week treatment periods in a cross-over design.
07/16/16 10:15 PMBad year for Wall Street's Golden Boy Ackman -
07/16/16 06:27 PMValeant Pharmaceuticals Intl Inc: Has VRX Stock Finally Bottomed? - Profit Confidential
07/16/16 10:21 AMValeant Pharmaceuticals International, Inc. (NYSE:VRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 08:28 PMU.S. Retail Sales Did Better Than Expected in June; the Nikkei 225 Had a Great Week: Best of Kass -
07/15/16 06:11 PMValeant’s stock chart warns not to board the bearish bandwagon
07/15/16 06:11 PMHere's Why Valeant Pharmaceuticals International, Inc. (VRX) Saw Sequoia Fund Liquidate Stake Last Quarter

Social

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: VRX
  • CUSIP:
Key Metrics:
  • Previous Close: $23.49
  • 50 Day Moving Average: $22.59
  • 200 Day Moving Average: $45.41
  • P/E Ratio: N/A
  • P/E Growth: 0.45
  • Market Cap: $8.06B
  • Beta: 0.21
  • Current Year EPS Consensus Estimate: $6.83 EPS
  • Next Year EPS Consensus Estimate: $8.13 EPS
Additional Links:
Valeant Pharmaceuticals International (NYSE:VRX) Chart for Thursday, July, 28, 2016